JNJ (STOCKS)
Johnson & Johnson
$238.050000
-0.410000 (-0.17%)
Prev close: $238.460000
Company Information
- Exchange
- XNYS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Joaquin Duato
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $572,840.51M
- Employees
- 139,800
- P/E (TTM)
- 21.61
- P/B (TTM)
- 7.04
- Dividend Yield
- 218.07%
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
6
Strong Buy
14
Buy
12
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$2.46 | $2.46 | -0.0033 | -0.13% |
|
Sep 2025 (Q3)
|
$2.80 | $2.78 | +0.0152 | +0.55% |
|
Jun 2025 (Q2)
|
$2.77 | $2.71 | +0.0622 | +2.30% |
|
Mar 2025 (Q1)
|
$2.77 | $2.61 | +0.1558 | +5.96% |
Financial Statements
| Revenues | $94.19B |
| Benefits Costs and Expenses | $61.61B |
| Cost Of Revenue | $30.26B |
| Costs And Expenses | $61.61B |
| Gross Profit | $63.94B |
| Operating Expenses | $31.36B |
| Selling, General, and Administrative Expenses | $23.68B |
| Research and Development | $109.00M |
| Other Operating Expenses | $7.57B |
| Operating Income/Loss | $32.58B |
| Income/Loss From Continuing Operations After Tax | $26.80B |
| Income/Loss From Continuing Operations Before Tax | $32.58B |
| Income/Loss From Discontinued Operations Net Of Tax | $0.00 |
| Income/Loss From Discontinued Operations Net Of Tax Gain/Loss On Disposal | $0.00 |
| Income Tax Expense/Benefit | $5.78B |
| Income Tax Expense/Benefit, Current | $4.24B |
| Income Tax Expense/Benefit, Deferred | $1.54B |
| Net Income/Loss | $26.80B |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | $26.80B |
| Net Income/Loss Available To Common Stockholders, Basic | $26.80B |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $11.13 |
| Diluted Earnings Per Share | $11.03 |
| Basic Average Shares | 2,407,400,000 |
| Diluted Average Shares | 2,429,400,000 |
| Common Stock Dividends | $5.14 |
| Assets | $199.21B |
| Current Assets | $55.62B |
| Inventory | $14.19B |
| Other Current Assets | $41.43B |
| Noncurrent Assets | $143.59B |
| Fixed Assets | $23.17B |
| Intangible Assets | $50.40B |
| Other Non-current Assets | $70.01B |
| Liabilities | $117.67B |
| Current Liabilities | $54.13B |
| Accounts Payable | $11.99B |
| Wages | $4.53B |
| Other Current Liabilities | $37.60B |
| Noncurrent Liabilities | $63.54B |
| Long-term Debt | $41.44B |
| Other Non-current Liabilities | $22.10B |
| Equity | $81.54B |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $81.54B |
| Liabilities And Equity | $199.21B |
| Net Cash Flow From Operating Activities | $24.53B |
| Net Cash Flow From Operating Activities, Continuing | $24.53B |
| Net Cash Flow From Investing Activities | -$23.59B |
| Net Cash Flow From Investing Activities, Continuing | -$23.59B |
| Net Cash Flow From Financing Activities | -$5.54B |
| Net Cash Flow From Financing Activities, Continuing | -$5.54B |
| Exchange Gains/Losses | $201.00M |
| Net Cash Flow | -$4.40B |
| Net Cash Flow, Continuing | -$4.60B |
| Comprehensive Income/Loss | $23.62B |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | $23.62B |
| Other Comprehensive Income/Loss | -$3.19B |